BPC-157 is not FDA-approved to treat, cure, or prevent any disease
A peer-reviewed study in the Journal of Pharmaceutical Sciences confirming that temperature and moisture are the primary drivers of lyophilized peptide degradation during storage provides the scientific basis for these refrigeration requirements
noted that there was " a strong protection, noted following [exposure to] BPC 157." BPC-157 also has the potential to enhance the function of the digestive tract and prevent against irritable bowel syndrome (IBS), gastrointestinal cramps, and Crohns disease
Cellular readouts in 3T3-L1 adipocytes: decreased 1-MNA, increased NAD and SAM, and reduced lipogenesis after 5-Amino-1MQ exposure [1,6,7]
So, doctors counter it by treating the underlying conditions
The escalation phases are only required during the first cycle